0.00Open0.00Pre Close0 Volume0 Open Interest12.50Strike Price0.00Turnover151.17%IV-38.42%PremiumDec 20, 2024Expiry Date7.80Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9194Delta0.0181Gamma2.48Leverage Ratio-0.0245Theta0.0076Rho2.28Eff Leverage0.0082Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet